Glatiramer acetate versus interferon Beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients

By Castelli-Haley Jane  

Advances in Therapy, Vol. 25, Iss. 8, 2008-08 ,pp. : 830-830

Springer Publishing Company

Access to resources Recommend Favorite

Dose response to interferon therapy in multiple sclerosis: an evaluation of the evidence

By Freedman S. Mitchell  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 547-557

Informa Healthcare

Access to resources Recommend Favorite

Antibodies to Commercially Available Interferon–Beta Molecules in Multiple Sclerosis Patients Treated with Natural Interferon–Beta

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 368-371

Karger

Access to resources Recommend Favorite

Comparison of ActiGraph activity monitors in persons with multiple sclerosis and controls

By Sandroff Brian M.   Motl Robert W.  

Disability and Rehabilitation, Vol. 35, Iss. 9, 2013-05 ,pp. : 725-731

Informa Healthcare

Access to resources Recommend Favorite

MxA Gene Expression Analysis as an Interferon- Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity

By Pachner A.R.   Narayan K.   Price N.   Hurd M.   Dail D.  

Molecular Diagnosis, Vol. 7, Iss. 1, 2003-01 ,pp. : 17-25

Adis International

Access to resources Recommend Favorite